A SARS-COV-2 Human Parainfluenza Virus Type 3-Vectored Vaccine
AssigneeBoard of Regents, The University of Texas System
InventorsAlexander Bukreyev, Philipp A. Ilinykh, Sivakumar Periasamy, Kai Huang
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to a new human parainfluenza virus (HPIV)/SARS-CoV-2 vaccine or vaccine construct/polynucleotide. Specifically, the HPIV is a Human parainfluenza virus type 3 (HIPV3), and the vaccine construct encoding a SARS-CoV-2 spike protein (S protein), that is a SARS-CoV-2 S protein S1 subunit and/or a SARS-CoV-2 S protein receptor binding domain (RBD), in certain aspects the vaccine or vaccine construct is administered via intranasal administration.
Claims19
A SARS-CoV-2 vaccine comprising an engineered Human parainfluenza virus (HPIV) encoding a SARS-CoV-2 spike protein (S protein) in a transcriptional cassette.
A human parainfluenza virus (HPIV)/SARS-CoV-2 construction comprising a HPIV genome having a SARS-CoV-2 transcription cassette, wherein the transcription cassette encodes for all or part of a SARS-CoV-2 spike protein.
Dependencies are inferred from the claim text.